• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: effect on regional blood flow, infarct size and hemostasis.

作者信息

Flameng W, Vanhaecke J, Stump D C, Van de Werf F, Holmes W, Guenzler W A, Flohe L, Collen D

出版信息

J Am Coll Cardiol. 1986 Jul;8(1):118-24. doi: 10.1016/s0735-1097(86)80101-2.

DOI:10.1016/s0735-1097(86)80101-2
PMID:3086416
Abstract

An occlusive thrombus was produced by thrombin-induced coagulation in the left anterior descending coronary artery of 18 open chest baboons. In six control animals, occlusive thrombosis persisting for 4 hours resulted in a large transmural infarct (66 +/- 4% of the perfusion area, mean +/- SEM). In six animals, single chain urokinase-type plasminogen activator, obtained by recombinant deoxyribonucleic acid (DNA) technology, was infused intravenously at a rate of 20 micrograms/kg per min for 60 minutes after approximately 45 minutes of coronary thrombosis. Persistent reperfusion occurred within 21 +/- 4 minutes (mean +/- SD). The mean duration of occlusion before reperfusion was 72 +/- 6 minutes. Recanalization resulted in a reduction of infarct size (42 +/- 4%, p less than 0.01 versus control animals). Myocardial blood flow in the perfusion area of the left anterior descending coronary artery was 107% of normal 2.5 hours after recanalization. The infusion of recombinant single chain urokinase-type plasminogen activator was not associated with systemic activation of the fibrinolytic system, fibrinogen breakdown or evident bleeding. In six baboons recombinant low molecular weight urokinase (molecular weight 33,000) was infused intravenously at a rate of 20 micrograms/kg per min for 60 minutes after approximately 45 minutes of coronary thrombosis. Persistent reperfusion occurred within 14 +/- 5 minutes (p less than 0.05 versus recombinant single chain urokinase-type plasminogen activator). The mean duration of occlusion was 69 +/- 14 minutes.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

相似文献

1
Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: effect on regional blood flow, infarct size and hemostasis.
J Am Coll Cardiol. 1986 Jul;8(1):118-24. doi: 10.1016/s0735-1097(86)80101-2.
2
Coronary thrombolysis and infarct size reduction after intravenous infusion of recombinant tissue-type plasminogen activator in nonhuman primates.在非人灵长类动物中静脉输注重组组织型纤溶酶原激活剂后的冠状动脉溶栓及梗死面积缩小情况。
J Clin Invest. 1985 Jan;75(1):84-90. doi: 10.1172/JCI111701.
3
Recombinant single-chain urokinase-type plasminogen activator during acute myocardial infarction.
Am J Cardiol. 1988 May 1;61(13):966-70. doi: 10.1016/0002-9149(88)90107-5.
4
Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.重组人组织型纤溶酶原激活剂与人类单链尿激酶型纤溶酶原激活剂的协同组合。对严重狭窄犬冠状动脉血栓形成模型中溶栓及再闭塞的影响。
Circulation. 1989 Feb;79(2):393-9. doi: 10.1161/01.cir.79.2.393.
5
Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.采用重组组织型纤溶酶原激活剂(rt-PA)和重组单链尿激酶型纤溶酶原激活剂(rscu-PA)低剂量协同组合进行冠状动脉溶栓治疗急性心肌梗死。
Am J Cardiol. 1987 Sep 1;60(7):431-4. doi: 10.1016/0002-9149(87)90280-3.
6
Coronary thrombolysis with human single-chain, urokinase-type plasminogen activator (pro-urokinase) in patients with acute myocardial infarction.
Ann Intern Med. 1986 Mar;104(3):345-8. doi: 10.7326/0003-4819-104-3-345.
7
Recombinant single-chain urokinase-type plasminogen activator (rscu-PA) induces thrombolysis and systemic fibrinolysis in a canine model of coronary artery thrombosis.
Thromb Res. 1988 Jul 1;51(1):63-74. doi: 10.1016/0049-3848(88)90283-6.
8
Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis.
J Cardiovasc Pharmacol. 1987 Jan;9(1):91-3.
9
Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.重组单链尿激酶型纤溶酶原激活剂(沙芦普酶)静脉推注或持续输注用于溶栓的比较。犬冠状动脉和股静脉联合血栓形成模型。
Blood. 1990 Oct 15;76(8):1558-63.
10
Enhancement of coronary thrombolysis with plasminogen pro-activator by pretreatment with heparin.
Jpn Circ J. 1988 Jan;52(1):72-8. doi: 10.1253/jcj.52.72.

引用本文的文献

1
Saruplase in Myocardial Infarction.沙芦普酶治疗心肌梗死
J Thromb Thrombolysis. 1995;2(3):195-204. doi: 10.1007/BF01062710.
2
A Double-Blind Multicenter Comparison of the Efficacy and Safety of Saruplase and Urokinase in the Treatment of Acute Myocardial Infarction: Report of the SUTAMI Study Group.沙芦普酶与尿激酶治疗急性心肌梗死疗效及安全性的双盲多中心比较:SUTAMI研究组报告
J Thromb Thrombolysis. 1995;2(2):117-124. doi: 10.1007/BF01064379.
3
Comparison of the Pharmacokinetics and Effects on the Hemostatic System of Saruplase and Urokinase in Patients with Acute Myocardial Infarction.
J Thromb Thrombolysis. 1996;3(4):385-390. doi: 10.1007/BF00133082.
4
Pharmacokinetics and hemostatic effects of saruplase in patients with acute myocardial infarction: comparison of infusion, single-bolus, and split-bolus administration.
J Thromb Thrombolysis. 1999 Oct;8(3):213-21. doi: 10.1023/a:1008914321384.